Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Yuanyuan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongyan Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoying Sun(Cancer Hospital of Huanxing Chaoyang District Beijing), Baolin Liu(Peking University), Ranran Gao(Peking University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zemin Zhang(Peking University), Zhihua Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 102Open Access
Abstract
T follicular helper (Tfh) cells. Nab-paclitaxel, unlike PTX, also reshapes the myeloid compartment, expanding mast cells and pro-inflammatory macrophages. Our analyses in human TNBC and murine models underscore the crucial role of mast cells in orchestrating anti-tumor immune responses, likely by promoting the recruitment and activation of T and B cells. In vivo experiments demonstrate that activating mast cells alongside PD-L1 blockade attenuates TNBC progression, suggesting mast cells as a promising adjunct for enhancing ICB therapy efficacy.
Related Papers
No related papers found
Powered by citation graph analysis